One Pill, Multiple Pathways for Immunological Disease: Our Investment in Coultreon Bio

April 2026

Chronic inflammatory disease treatment has been transformed over the past three decades by blockbuster biologic franchises such as Humira, Stelara, and many others (combine for >$40bn in top line sales and have treated millions of patients). Despite arising from a highly complex immune landscape, the commercial winners have largely followed a common playbook: target a single cytokine or pathway node to suppress a key driver of inflammation. This precision has transformed care for many patients, but it has also imposed a structural ceiling on efficacy. As in oncology, these narrowly targeted therapies tend to work best in biologically enriched populations. 

In chronic inflammatory indications such as inflammatory bowel disease (“IBD”), underlying patient heterogeneity has constrained the impact of these drugs and left many patients underserved. Subsequent innovation has expanded into adjacent cytokines, receptors, and other pathway selective approaches, often in pursuit of addressing more patients.

Yet even with these advances, durable efficacy ceilings remain in many chronic inflammatory indications.

The implication is increasingly clear: the next step forward will not come from pursuing ever more refined versions of the same single target paradigm. It will come from therapeutics capable of modulating multiple validated inflammatory pathways simultaneously, ideally in a convenient oral form. Given the coordinated behavior of key cytokines across immune states, a therapy that can unlock this biology and impact several proven mediators at once has the potential to reset the standard of care and create the next great franchise in chronic inflammatory disease.

That thesis underpins our investment in Coultreon Bio. The company is developing a selective SIK3 inhibitor designed to suppress both TNF-alpha and IL-23 while upregulating IL-10, three of the most central cytokines underlying inflammation in diseases such as psoriasis and IBD. If successful, Coultreon could deliver best in disease efficacy in a single, once daily oral therapy. We believe the field must move beyond single target cytokine inhibition, and Coultreon is positioned to define the next chapter of innovation in chronic inflammatory disease.

Breaking the Efficacy Ceiling in Chronic Inflammatory Diseases 

The efficacy ceiling in IBD has emerged over the past 30 years of clinical trials. For decades, new antibodies that inhibit a single inflammatory pathway show efficacy in these trials, but only in a minor subset of patients.

Coultreon’s lead program, O3R-5671, takes a different approach. This molecule inhibits the SIK3 pathway, a novel, first-in-class target that regulates the release of three key inflammatory molecules implicated in IBD, TNFα, IL-23, and IL-10. This unique approach inhibits two clinically validated pro-inflammatory targets (i.e., TNFα and IL-23) while simultaneously promoting an anti-inflammatory state (i.e., IL-10), combining several biological nodes into a single therapy.

At Luma Group, we are firm believers in the ability of differentiated data sets to drive asymmetrical upside and the years of work that went in O3R-5671 are emblematic of this. Although it may be a first-in-class target, Coultreon’s SIK3 program has been battled-tested over the course of 10+ years of incubation, R&D development, and clinical trial experience at Galapagos. Unlike most biotech companies, which rely on preclinical studies in animal models to predict drug success, the Coultreon team has proprietary clinical data in patients from previous SIK programs to inform the Company’s current approach. The team leverages a proprietary AI-augmented drug design platform trained on a privately generated dataset of >300,000 compounds to integrate AI‑driven modelling, structure‑based design, early safety prediction and human dose projections, together with expert medicinal chemistry into a continuous learning loop that optimises lead assets for clinical success. The result is an optimized molecule that balances strong efficacy with a cleaner safety profile, avoiding the toxicities that plagued previous iterations of SIK programs.

Coultreon’s data from their Phase 1 clinical trial validates this thesis: O3R-5671 is safe and well-tolerated in healthy volunteers and achieves levels of target inhibition comparable to the existing TNFα and IL-23 antibody therapies.

Beyond Coulteon’s proprietary data, new data sets in IBD have begun to demonstrate the promise in dual targeting. Early clinical data from Johnson & Johnson’s VEGA trial has shown that hitting both the TNFα and IL-23 pathways together can potentially overcome the longstanding efficacy ceiling in ulcerative colitis with biologics.[1] O3R-5671 will not only have the potential to reproduce the VEGA results but will also have the upside of added IL-10 production in the convenience of a pill. These results add additional validation to the Coultreon approach and are an exciting glimmer for the potential future direction of the field.

A Better Product: Closing the Gap Between Injectable Efficacy and Oral Convenience

One of the clearest north stars in chronic inflammatory disease drug development has been to replicate the efficacy of injectable biologics in the convenience of an oral pill. Most blockbuster psoriasis and IBD therapies today are monoclonal antibodies and still carry the burdens of injectable treatment. In addition to frequent injections, these drugs often require cold storage, administration support, and other logistical steps that create friction for patients.

Oral small molecules such as O3R-5671 offer a simpler and more convenient alternative: a pill that can be taken without specialized training or the need for a doctor’s visit. For patients who may remain on therapy for much of their lives, reducing that treatment burden is not just a convenience goal, but essential to improving the long-term quality of their care.

The Case for Coultreon: Experience, Unmet Need, and Platform Scale

Luma Group has been focused on identifying and investing in the autoimmune space since day one. Coultreon’s approach stood out immediately as a rare opportunity to provide a step-change solution for patients in need. As we dug in deeper, we found numerous reasons to be excited about this opportunity, a few highlighted here:

Battle Tested Approach: Unlike many first-in-class medicines, the biological rationale for Coultreon’s program has been incubated for over a decade at Galapagos. The team has leveraged learnings from previous attempts to inform the current program. In drug discovery, human clinical data is the ultimate north star to guide drug design, as preclinical models can only do so much. In the case of Coultreon, no other organization has the same clinical SIK pathway institutional knowledge, and that battled tested experience has put them in pole position for success. 

Clear Need for Innovation: IBD and psoriasis are chronic conditions, and once they are diagnosed, patients stay on therapies for the rest of their lives. Even in the age of advanced antibody therapy, as many as 20% of IBD patients require surgery to remove portions of their GI tract. Using antibodies to target a single inflammatory pathway has failed for patients, and the field has a clear need for novel approaches. While treatment options are much better in psoriasis, patients still lack effective oral options leaving persistent need for innovation. Coultreon’s SIK3 inhibitor brings a combination therapy in the form of a pill, potentially solving key unmet needs across multiple indications.

Outsized Impact in Multiple Indications: O3R-5671 is a true “pipeline in a pill.” In addition to IBD, the company will also run a Phase 2 proof of concept trial in psoriasis and has plans to expand into other indications once they establish the clinical efficacy of their drug. Like many autoimmune drugs, O3R-5671’s impact will not just be limited to one chronic inflammation indication, but over half a dozen that will reach millions of patients.

The outsized impact on human health that a molecule could make here could be dramatic. We are proud to support the Coultreon Bio team as they embark on their ambitious mission.

Backing the Next Standard of Care in Autoimmune Disease

At Luma Group, we aim to work closely with drug developers who are making treatments that can reset the bar for patient outcomes. Setting the bar is Coultreon’s mission, leveraging their institutional knowledge and expertise to bring life-changing medicine to autoimmune disease patients. We are proud to support them as they work to break above the efficacy ceiling and bring transformational therapies to patients.